FINWIRES · TerminalLIVE
FINWIRES

Eco (Atlantic) Oil & Gas Farms Down Namibia Portfolio to BP

-- Eco (Atlantic) Oil & Gas (EOG.V) on Monday said it has signed an agreement to farm down 60% participating interest in all three of its petroleum exploration licenses offshore Namibia to BP Namibia Energy.

Under the agreement, Eco subsidiaries will farm out an aggregate of 60% participating interest and transfer operatorship to BP of Block 2012A PEL97, Blocks 2111B and 2211A PEL99, and blocks 2211B and 2311A PEL100.

At deal completion, Eco will retain a 25% interest in PEL97, PEL99 and PEL100. Deal completion is subject to customary conditions and approvals from the Namibian authorities, Ministry of Industries Mines and Energy and Upstream Petroleum Unit at the State House.

A one-time cash consideration of US$2.7 million is payable at deal completion.

If BP and its partners elect to enter the second renewal period of the license term in 2028 and commit to drilling an exploration well, Eco will have the option to either exercise a put option to transfer an additional 10% participating interest to BP in exchange for a full carry on Eco's remaining 15% participating interest subject to a cap of $21 million net to Eco for each well on each of the licenses; or elect to retain its 25% participating interest of the costs associated with such drilling of a well during the second renewal period.

The maximum aggregate carry consideration payable by BP in respect of each put option is $63 million with a cap of $21 million per put option.

Eco can elect to retain its 25% paying interest or to farm out to other potential partners.

Eco will use deal proceeds to support its ongoing exploration and appraisal activities across its Atlantic Margin portfolio and for general working capital purposes.

相關文章

Asia

Dizal Pharma將在美國臨床腫瘤學會年會上發表三種藥物的研究成果。

根據週三在上海證券交易所發布的公告顯示,江蘇迪扎爾製藥(SHA:688192)表示,將在美國臨床腫瘤學會(ASCO)年會上公佈其新藥sunvozertinib片劑、golidocitinib膠囊和DZD6008的最新研究成果。 sunvozertinib和DZD6008皆用於治療非小細胞肺癌,而golidocitinib則用於治療T細胞淋巴瘤。研究結果顯示,這些藥物均取得了正面成果,尤其是DZD6008,其具有顯著的抗腫瘤活性且安全性良好。 該生技公司的股價在午盤交易中上漲不到2%。

$SHA:688192
Asia

Critica將於3月季度啟動西澳大利亞稀土計畫範圍界定研究。

根據週三提交給澳洲證券交易所的文件顯示,Critica(ASX:CRI)表示,位於西澳大利亞的Jupiter稀土計畫的初步研究已於今年3月季度正式啟動。 該研究整合了選礦、下游加工、基礎設施和開發假設,旨在確定一個基準開發路徑。 公司計劃在6月季度繼續完成Jupiter專案140個鑽孔的資源升級鑽探工作。此外,該公司還計劃準備並運送20,000公斤散裝樣品進行中試規模處理,以支援持續的最佳化、性能提升和中間精礦的生產。

$ASX:CRI
Asia

北太平洋銀行的收購要約確保了對卡里爾銀行的控制權

北太平洋銀行(東京證券交易所代號:8524)週三在東京證券交易所發佈公告稱,其對Career Bank的股份收購要約已獲成功,持股比例增至88.26%,使Career Bank成為其子公司。 北太平洋銀行此次收購了852,487股Career Bank股份,超過了完成交易所需的最低收購數量。 交易結算將於4月28日開始,屆時Career Bank將正式併入北太平洋銀行的財務報表。 北太平洋銀行計劃啟動相關程序,使Career Bank成為其全資子公司,並將其股票從札幌證券交易所下市。此次收購總成本約為15億日圓。

$TYO:8524